Kane Biotech Inc., located in Winnipeg, Manitoba, is a biotechnology company focused on developing technologies and products to combat biofilms and bacteria. With over 20 years of experience, their R+D division has generated 66 patents and patents pending in biotechnology, particularly in the field of biofilm disruption.
The company's subsidiary, Kane Wound Care & Surgical, aims to address the global wound care market, projected to reach US $22 billion by 2022. Meanwhile, Kane Dermatology focuses on creating non-prescription consumables to tackle minor health issues exacerbated by biofilms.
By conducting extensive consumer trials and utilizing innovative technologies like coactiv+™, Kane Biotech offers products such as revyve™ Antimicrobial Wound Gel and DermaKB™ Scalp Detoxifier to provide effective solutions for various health concerns. With a commitment to research and development, Kane Biotech remains dedicated to advancing biofilm-disrupting technologies for improved health outcomes.
Generated from the website content
